June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Weekly dosing regimen of eye drop formulations delivered through mucoadhesive nanoparticles enhances treatment of experimental dry eye
Author Affiliations & Notes
  • Shengyan Liu
    Chemical Engineering - Nanotechnology, University of Waterloo, Waterloo, ON, Canada
  • Matthew Daniel Dozois
    Chemical Engineering - Nanotechnology, University of Waterloo, Waterloo, ON, Canada
  • Deborah Li Ting Ng
    Chemical Engineering - Nanotechnology, University of Waterloo, Waterloo, ON, Canada
  • Chuning Chang
    Chemical Engineering - Nanotechnology, University of Waterloo, Waterloo, ON, Canada
  • Denise Hileeto
    Optometry & Vision Science, University of Waterloo, Waterloo, ON, Canada
  • Lyndon William Jones
    Optometry & Vision Science, University of Waterloo, Waterloo, ON, Canada
  • Frank Gu
    Chemical Engineering - Nanotechnology, University of Waterloo, Waterloo, ON, Canada
  • Footnotes
    Commercial Relationships Shengyan Liu, WO2013188979 A1 (P); Matthew Dozois, None; Deborah Ng, None; Chuning Chang, None; Denise Hileeto, None; Lyndon Jones, WO2013188979 A1 (P); Frank Gu, WO2013188979 A1 (P)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5036. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shengyan Liu, Matthew Daniel Dozois, Deborah Li Ting Ng, Chuning Chang, Denise Hileeto, Lyndon William Jones, Frank Gu; Weekly dosing regimen of eye drop formulations delivered through mucoadhesive nanoparticles enhances treatment of experimental dry eye. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5036.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract 
 
Purpose
 

To evaluate the long term efficacy of using once a week dosing of Cyclosporine A (CsA) loaded mucoadhesive nanoparticle eye drop formulation in treating dry eye syndrome (DES).

 
Methods
 

Experimental DES in mice was induced by applying scopolamine patches to their midtails and exposing them to desiccating environments. These mice were treated with various formulations including Restasis (thrice daily), nanoparticles without CsA (Blank NPs, once a week), CsA-loaded nanoparticles with a CsA dosage 1-2% that of Restasis (CsA-NP 1-2%, once a week) or CsA-NP 5% (once a week) for a month. Dry eye status was evaluated using tear production measurement, corneal fluorescein clearance, and histopathology analysis.

 
Results
 

After 4 weeks of treatment period, the once a week administration of CsA-NP 5% and thrice daily administration of Restasis both showed elimination of inflammatory signs, but did not recovery the integrity of the ocular surface tissues. The once a week administration of CsA-NP 1-2% showed both the elimination of the inflammation and full recovery of the ocular surface.

 
Conclusions
 

Weekly dosing regimen of CsA loaded mucoadhesive nanoparticle eye drop platform demonstrated effective treatment of experimental dry eye in mice with up to 50 to 100 fold reduction in overall dosage compared to Restasis, which may significantly reduce side effects and improve patient compliance.  

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×